Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.
复制标题
DOI：
10.1093/annonc/mdv257
复制
发表时间：
2015-08
期刊：
影响因子：
--
通讯作者：
Tombal B
中科院分区：
文献类型：
--
作者：
Gillessen S;Omlin A;Attard G;de Bono JS;Efstathiou E;Fizazi K;Halabi S;Nelson PS;Sartor O;Smith MR;Soule HR;Akaza H;Beer TM;Beltran H;Chinnaiyan AM;Daugaard G;Davis ID;De Santis M;Drake CG;Eeles RA;Fanti S;Gleave ME;Heidenreich A;Hussain M;James ND;Lecouvet FE;Logothetis CJ;Mastris K;Nilsson S;Oh WK;Olmos D;Padhani AR;Parker C;Rubin MA;Schalken JA;Scher HI;Sella A;Shore ND;Small EJ;Sternberg CN;Suzuki H;Sweeney CJ;Tannock IF;Tombal B
第一届圣加仑晚期前列腺癌共识会议（APCCC）专家小组确定并审查了晚期前列腺癌管理中十个最重要争议领域的现有证据。提出了基于专家意见的建议。关于治疗的详细决定将涉及对疾病程度和位置、既往治疗、宿主因素、患者偏好以及后勤和经济限制的临床考虑。第一届圣加仑晚期前列腺癌共识会议（APCCC）专家小组确定并审查了晚期前列腺癌（APC）治疗中十个最重要的争议领域的现有证据。一些治疗去势抵抗性前列腺癌的药物的成功注册，以及最近对castration-naïve前列腺癌男性的化学激素治疗的研究，导致了关于最佳治疗选择、治疗方案顺序和适当患者选择的相当大的不确定性。提出了基于专家意见的管理建议，而不是基于对现有证据的批判性审查。不同的建议得到了不同程度的支持，这反映在文章文本的措辞和详细的投票结果中，记录在补充材料中，可在肿瘤学年鉴在线上获得。一如既往，治疗的详细决定将涉及考虑疾病程度和位置、既往治疗、宿主因素、患者偏好以及后勤和经济限制。应鼓励将患有APC的男性纳入临床试验。
The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed available evidence for the ten most important areas of controversy in advanced prostate cancer management. Recommendations based on expert opinion are presented. Detailed decisions on treatment will involve clinical consideration of disease extent and location, prior treatments, host factors, patient preferences and logistical and economic constraints. The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for the ten most important areas of controversy in advanced prostate cancer (APC) management. The successful registration of several drugs for castration-resistant prostate cancer and the recent studies of chemo-hormonal therapy in men with castration-naïve prostate cancer have led to considerable uncertainty as to the best treatment choices, sequence of treatment options and appropriate patient selection. Management recommendations based on expert opinion, and not based on a critical review of the available evidence, are presented. The various recommendations carried differing degrees of support, as reflected in the wording of the article text and in the detailed voting results recorded in supplementary Material, available at Annals of Oncology online. Detailed decisions on treatment as always will involve consideration of disease extent and location, prior treatments, host factors, patient preferences as well as logistical and economic constraints. Inclusion of men with APC in clinical trials should be encouraged.